Stockscreener 앱 받기
3.23
6.38%
-0.22
시간 외 거래:
3.28
0.05
+1.55%
전일 마감가:
$3.45
열려 있는:
$3.42
하루 거래량:
574.18K
Relative Volume:
0.86
시가총액:
$200.32M
수익:
-
순이익/손실:
$-73.79M
주가수익비율:
-1.7554
EPS:
-1.84
순현금흐름:
$-77.44M
1주 성능:
+26.67%
1개월 성능:
+77.47%
6개월 성능:
+253.01%
1년 성능:
+1.25%
1일 변동 폭
$3.18
$3.45
1주일 범위
$2.56
$3.8851
52주 변동 폭
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
PYXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.23 | 213.96M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
What makes Pyxis Oncology Inc. stock attractive to growth fundsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Yahoo Finance
Why Pyxis Oncology Inc. stock is a value investor pickWeekly Stock Analysis & Risk Managed Investment Strategies - newser.com
Will Pyxis Oncology Inc. stock continue upward momentumMarket Growth Report & Community Consensus Picks - newser.com
Strategies to average down on Pyxis Oncology Inc.2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Pyxis Oncology to Present Translational Data and Key - GlobeNewswire
ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan
Smart tools for monitoring Pyxis Oncology Inc.’s price action2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Can Pyxis Oncology Inc. stock beat analyst upgradesTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
How risky is Pyxis Oncology Inc. stock nowJuly 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Will Pyxis Oncology Inc. stock deliver better than expected guidance2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Full technical analysis of Pyxis Oncology Inc. stockJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Developing predictive dashboards with Pyxis Oncology Inc. data2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
Pyxis Oncology Gains 70%, Insider Trades Reap Benefit - 富途牛牛
Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Will Pyxis Oncology Inc. see short term momentumVolume Spike & Pattern Based Trade Signal System - newser.com
Is Pyxis Oncology Inc. stock undervalued vs historical averages2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Is Pyxis Oncology Inc. stock a top pick in earnings seasonRate Cut & AI Enhanced Trading Signals - newser.com
Real time pattern detection on Pyxis Oncology Inc. stockMarket Growth Report & Community Consensus Picks - newser.com
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025 - MarketScreener
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com Australia
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Quiver Quantitative
Pyxis Oncology appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - MarketScreener
Volume spikes in Pyxis Oncology Inc. stock – what they mean2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Pyxis Oncology Inc.’s future2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Pyxis Oncology Inc. stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
What to do if you’re stuck in Pyxis Oncology Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - newser.com
Sector ETF performance correlation with Pyxis Oncology Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Pyxis Oncology Inc.July 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Quantitative breakdown of Pyxis Oncology Inc. recent move2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - newser.com
Live market analysis of Pyxis Oncology Inc.July 2025 Intraday Action & Growth Oriented Trade Recommendations - newser.com
Can swing trading help recover from Pyxis Oncology Inc. lossesAnalyst Downgrade & Pattern Based Trade Signal System - newser.com
Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance
What analysts say about Pyxis Oncology Inc stockHigh Frequency Trading Trends & Next-Level Stock Intelligence, Now Free - earlytimes.in
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.15%
1.45%
자본화:
|
볼륨(24시간):